Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
The Federal Reserve focuses on structural changes in inflation and the risks of an AI investment bubble

The Federal Reserve focuses on structural changes in inflation and the risks of an AI investment bubble

AiCoinAiCoin2026/06/04 09:53
Show original
The Federal Reserve Beige Book indicates a "dual-sided economy" phenomenon in the United States: In May, private sector employment increased by 122,000 jobs, capital expenditure was driven by AI data center construction, Alphabet's financing scale rose to $84.75 billion, and SpaceX valuation is nearing $1.8 trillion; however, consumer confidence has dropped to a historic low, real wages have declined, and some companies have postponed investment plans. Current core inflation stands at 3.8%, above the 2% target, mainly fueled by energy, tariffs, and AI capital expenditure. New York Federal Reserve President Williams believes there is no need to raise rates for now, while Dallas Federal Reserve President Logan stated that further rate hikes may be needed this year. Bridgewater founder Dalio warns that AI investments may exhibit bubble characteristics, and the market should pay attention to the alignment between valuations and profitability. The world's first ETF, VOO, to exceed $1 trillion in scale has been born, with funds concentrated among a handful of leading companies.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage